Patent intelligence · US
US 11236141
Targeted mutant interferon-beta and uses thereof
Targeted mutant interferon-beta and uses thereof
Patent details — US 11236141
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 1, 2022
- Expiration
- Jan 27, 2042
- Applicant
- Orionis Biosciences, Inc
- Claims
- 16
- CPC classes
- A61K, A61K38/00, A61K47/65, A61P
Quick answer
US 11236141 (Targeted mutant interferon-beta and uses thereof) is held by Orionis Biosciences, Inc. Status: granted. Granted Feb 1, 2022. Expires Jan 27, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Orionis Biosciences, Inc
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K38/00, A61K47/65, A61P, A61P35/00, A61P37/06
More from Orionis Biosciences, Inc
Related pharmaceutical patents in our USPTO index.
-
US 12409188
Modulators of HSD17B13 expression
granted -
US 12410225
Modulation of dendritic cell lineages
granted -
US 12410430
Modulating apolipoprotein (A) expression
granted -
US 12364753
CD8 binding agents
granted -
US 12351633
PD-1 and PD-L1 binding agents
granted -
US 12350285
Compounds and methods for reducing ATXN3 expression
granted -
US 12351614
CLEC9A-based chimeric protein complexes
granted -
US 12343357
Compositions and methods for modulating MECP2 expression
granted
Frequently asked questions
What is US patent 11236141?
US 11236141 (Targeted mutant interferon-beta and uses thereof) is held by Orionis Biosciences, Inc. Status: granted. Granted Feb 1, 2022. Expires Jan 27, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11236141?
Orionis Biosciences, Inc is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 222 pharmaceutical patents for this assignee.
When does US 11236141 expire?
Our index shows an expiration date of Jan 27, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.